前蛋白转化酶枯草溶菌素9抑制剂的临床研究及应用进展
Progress in research and clinical application of proprotein convertase subtilisin kexin type 9 inhibitors in the treatment of dyslipidemia
赵瑾 1陈鹏飞 2包楠迪2
作者信息
- 1. 中国人民解放军总医院京北医疗区红山口门诊部,北京 100091
- 2. 中国人民解放军总医院第六医学中心心血管病医学部,北京 100853
- 折叠
摘要
前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂可通过抑制肝细胞表面低密度脂蛋白受体的降解对脂质代谢起到调节作用.目前已有多项临床研究证明,PCSK9抑制剂单一药物或与他汀类药物联合使用可显著降低低密度脂蛋白胆固醇水平.本文综述了当前PCSK9抑制剂的重要临床研究及应用进展,并简要总结了常见PCSK9抑制剂的安全性、有效性及临床应用现状.
Abstract
Proprotein convertase subtilisin kexin type 9(PCSK9)inhibitors regulate lipid metabolism by inhibiting the degradation of low-density lipoprotein receptors on the surface of hepatocytes.Multiple clinical studies have demonstrated that the use of PCSK9 inhibitors as monotherapy or in combination with statins can significantly reduce levels of low-density lipoprotein cholesterol.This article reviews the significant clinical research and progress in the application of PCSK9 inhibitors and briefly summarizes their safety,efficacy and clinical applications.
关键词
前蛋白转化酶枯草溶菌素9/低密度脂蛋白胆固醇/脂质代谢/动脉粥样硬化Key words
proprotein convertase subtilisin kexin type 9/low-density lipoprotein cholesterol/lipid metabolism/atherosclerosis引用本文复制引用
基金项目
解放军总医院青年自主创新科学基金(22QNFC051)
出版年
2024
NETL
NSTL
维普
万方数据